GlassScriptPhysician profile
Xiang Qian
NPI 1669634226
$15,336.63
in general payments reported to CMS, 2019-2025
10 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.53 · 2021: $202 · 2022: $264 · 2023: $136 · 2024: $165 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,400.00 |
| Food and Beverage | $451.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $14,400.00 | 2025 | |
| Abbott Laboratories | $230.05 | 2021-2022 | |
| Medtronic, INC. | $165.09 | 2024 | Intellis Adaptivestim |
| Nevro Corp. | $155.51 | 2019-2023 | Senza |
| Beigene USA, INC. | $150.00 | 2025 | Brukinsa |
| Vertos Medical, INC. | $131.58 | 2022 | |
| Spr Therapeutics, INC | $85.81 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Stimwave Technologies Incorporated | $6.43 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,252,260.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiang Qian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.